Rodney Dawson Selected Research

Duration of Therapy

1/2021	Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin.
1/2018	The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rodney Dawson Research Topics

Disease

44	Tuberculosis (Tuberculoses) 05/2024 - 08/2008
20	Pulmonary Tuberculosis 01/2024 - 08/2010
6	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 01/2023 - 06/2012
3	Infections 01/2023 - 08/2008
3	HIV Infections (HIV Infection) 10/2021 - 08/2008
2	Acquired Immunodeficiency Syndrome (AIDS) 01/2023 - 01/2021
2	Body Weight (Weight, Body) 05/2015 - 06/2012
1	Extrapulmonary Tuberculosis 10/2021
1	Granuloma 10/2021
1	Pleural Tuberculosis 10/2021
1	Substance-Related Disorders (Drug Abuse) 01/2021
1	Cardiac Arrhythmias (Arrythmia) 01/2021
1	Extensively Drug-Resistant Tuberculosis 01/2021
1	Emphysema 01/2020
1	Heart Failure 01/2020
1	Hematuria 01/2017
1	Coinfection 01/2017
1	Ventricular Tachycardia 05/2015
1	Reinfection 12/2013
1	Pericarditis 11/2011
1	Pleural Effusion (Pleural Effusions) 01/2009

Drug/Important Bio-Agent (IBA)

24	Rifampin (Rifampicin)FDA LinkGeneric 05/2024 - 05/2011
9	Pyrazinamide FDA LinkGeneric 01/2023 - 07/2013
9	pretomanidIBA 01/2023 - 08/2010
8	Isoniazid (Ftivazide)FDA LinkGeneric 01/2021 - 05/2015
7	Ethambutol (Myambutol)FDA LinkGeneric 01/2023 - 05/2015
6	Moxifloxacin (Avelox)FDA Link 01/2023 - 07/2013
5	bedaquiline (R207910)IBA 01/2024 - 05/2013
3	RifamycinsIBA 01/2023 - 01/2019
3	rifapentine (Priftin)FDA Link 01/2023 - 01/2019
3	Linezolid (Zyvox)FDA Link 01/2021 - 01/2020
2	VaccinesIBA 04/2024 - 01/2017
2	Anti-Bacterial Agents (Antibiotics)IBA 02/2023 - 10/2021
2	thiamine triphosphorate (TTP)IBA 01/2023 - 12/2019
2	APTIBA 01/2023 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2023 - 08/2013
2	NitroimidazolesIBA 01/2023 - 01/2021
2	Clofazimine (Lamprene)FDA Link 01/2021 - 04/2015
2	Tuberculin (PPD)IBA 01/2020 - 08/2008
2	Adenosine DeaminaseIBA 01/2014 - 01/2009
1	dolutegravirIBA 05/2024
1	OPC-67683IBA 01/2024
1	Rifabutin (Ansamycin)FDA Link 01/2021
1	Antitubercular AgentsIBA 01/2021
1	Interferon-gamma (Interferon, gamma)IBA 01/2020
1	Triglycerides (Triacylglycerol)IBA 01/2020
1	9 alpha,11 alpha,15 alpha- trihydroxy- 16- phenoxy- 17,18,19,20- tetranorprosta- 4,5,13- trienoic acid (TPT)IBA 01/2020
1	EnzymesIBA 01/2018
1	AERAS-402IBA 01/2017
1	AcidsIBA 01/2017
1	Tuberculosis VaccinesIBA 01/2017
1	Indicators and Reagents (Reagents)IBA 05/2015
1	RNA (Ribonucleic Acid)IBA 01/2014
1	PNU-100480IBA 01/2014
1	AerosolsIBA 01/2014
1	dimemorfan (AT 17)IBA 12/2013
1	DNA (Deoxyribonucleic Acid)IBA 08/2013
1	CytokinesIBA 01/2013
1	Interleukin-22 (IL-22)IBA 11/2011
1	Interleukin-17 (Interleukin 17)IBA 11/2011
1	AntigensIBA 01/2009
1	lipoarabinomannan (LAM)IBA 01/2009
1	Nucleic AcidsIBA 01/2009

Therapy/Procedure

10	Therapeutics 01/2020 - 08/2010
3	Aftercare (After-Treatment) 01/2020 - 08/2013
2	Duration of Therapy 01/2021 - 01/2018
2	Drug Therapy (Chemotherapy) 11/2018 - 01/2018
1	Secondary Prevention 01/2021
1	Art Therapy 04/2017